Therapy and Peer Support for Patients Taking Medication for Opioid Use Disorder
- Conditions
- Opioid-use Disorder
- Interventions
- Behavioral: Psychosocial treatment
- Registration Number
- NCT06359340
- Lead Sponsor
- Public Health Management Corporation
- Brief Summary
Current clinical guidelines for medication assisted treatment (MAT) of opioid use disorder (OUD) recommend that treatment include a psychosocial component to help address psychological factors related to addiction. However, a knowledge gap exists regarding the most effective forms of psychosocial intervention and what interventions are most effective for different types of patients. This gap represents a significant barrier to the widespread implementation of effective office-based opioid treatment (OBOT) with buprenorphine, which is important to improving opioid treatment and responding to the critical needs of individuals living with OUD. The overarching goal of this patient-centered research is to address the diverse needs and preferences of OUD patients in regards to psychosocial approaches and to overcome the "one-size-fits-all" strategies that are typically used to treat OUD. Importantly, the investigators arrived at this goal, in part, through collaboration and consultation with former patients who have received different types of treatments for OUD. In this manner, patients provided important insight to inform the selection of interventions to be evaluated, patient characteristics that may differentially impact the effects of the interventions, and the patient outcomes to be examined.
- Detailed Description
The study will evaluate the comparative effectiveness of two psychosocial approaches, Cognitive Behavioral Therapy and peer support through the use of Certified Recovery Specialists provided within the context of office-based buprenorphine treatment. Patients will be randomly assigned to receive either (1) standard Medication Management (MM) as typically provided at the site, (2) MM with office-based CBT, (3) MM with CRS, and (4) MM with both CBT and CRS. In MM, patients will be seen by providers at least weekly until stable, and stabilized patients will then be seen by the provider on a monthly basis. If a patient needs a higher level of care, they will be referred to appropriate specialty treatment to ensure their safety. In the CBT study arms, CBT will be provided through 12 individual manualized sessions scheduled to coincide with patients' MM appointments when possible. As outlined by the National Institute on Drug Abuse (NIDA), sessions will cover standard CBT topics and include exercises and homework. Meta-analyses and reviews have concluded that CBT is an effective treatment across a range of SUDs and has helped to enhance treatment retention, improve medication adherence, and address ancillary problems. In the CRS study arms, CRS's will meet with clients following their first OBOT session to assist them in accessing community resources and overcoming treatment barriers, and provide ongoing patient navigation services to promote attendance at OBOT appointments. These appointments will occur either in-person or over the phone and all meetings will be tracked by the CRS. Studies indicate that peer-delivered services for individuals with mental health disorders are effective in engaging "difficult-to-reach" individuals and improving multidimensional outcomes. In the combined CBT/CRS study arm, clients will receive the individual CBT sessions and be assigned to a CRS.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 440
- Adults (≥18 years)
- Meet DSM 5 criteria for moderate to severe OUD;
- Be deemed eligible for buprenorphine treatment for OUD by the FQHC treatment provider and agree to engage in this treatment;
- Not require an inpatient level of care as determined by the healthcare provider;
- Be capable of providing valid contact information and informed consent; and
- Permit the research team to use and disclose their protected health information (PHI).
Individuals who are intoxicated, cognitively impaired, or psychiatrically unstable at baseline will not be included; however, they may subsequently be included if the disqualifying condition subsides.
DSM 5 criteria for OUD include:
- Taking opioids in larger amounts or longer than intended;
- Failed efforts to quit or cut back;
- Spending a lot of time obtaining the opioid;
- Craving or urges to use;
- Repeated inability to carry out major work, school, or home obligations;
- Continued use despite persistent or recurring interpersonal problems worsened by opioid use;
- Stopping or reducing important social, recreational activities due to opioid use;
- Recurrent use of opioids in physically hazardous situations;
- Continued opioid use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance;
- Tolerance; and
- Withdrawal. Moderate OUD severity is denoted by the presence of 4 or 5 of these symptoms and severe OUD is denoted by 6 or more symptoms. Patients will be excluded from the study if their SUD is primarily for a different substance, or their co-morbid psychiatric needs indicate enhanced needs.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Arm && Interventions
Group Intervention Description MAT+ both CBT and CRS/Peer Support Specialist Psychosocial treatment Those randomized to MAT+ office-based CBT will receive office-based buprenorphine treatment along with office-based CBT and a CRS. MAT+ office-based CBT Psychosocial treatment Those randomized to MAT+ office-based CBT will receive office-based buprenorphine treatment along with office-based CBT. MAT- OBOT Psychosocial treatment Those randomized to MAT standard of care will continue to receive standard office-based buprenorphine treatment. MAT+ CRS/Peer Support Specialist Psychosocial treatment Those randomized to MAT+ office-based CBT will receive office-based buprenorphine treatment along with a CRS.
- Primary Outcome Measures
Name Time Method Changes in urinalysis-confirmed opioid use from baseline through one year post-study entry At baseline and 3,6,9, 12-month assessments Participants will provide a urine specimen at baseline and 3, 6, 9, and 12-month assessments. Investigators will use the CLIA Waived® 14-Panel Drug Test Cup and fentanyl test strip for opioids, buprenorphine, methadone, oxycodone, THC, cocaine, amphetamines, PCP, methamphetamine, benzodiazepines, and barbiturates, and MDMD. The urine sample will be delivered under the supervision of the RA who will use standard procedures to detect tampering and dilution.
- Secondary Outcome Measures
Name Time Method Changes in the percentage of individuals engaging in urinalysis-confirmed use of other (non-opioid) drugs from baseline to one year post-study entry At baseline and 3,6,9, 12-month assessments Results from the CLIAwaived® 14-panel test and fentanyl strip described above for the primary outcome will be used as an indicator of this outcome. A binary variable reflecting other drug use versus no other drug use will be generated for this outcome.
Days Retained in Office-Based Buprenorphine Treatment Through 12 months Information from the electronic health record (EHR) will be used to determine the number of days of engagement in OBOT. Investigators will obtain data from the EHR reflecting OBOT-related data including appointments attended, prescription refill information, and service dates. A patient will be identified as having dropped out of OBOT when 30 days without current buprenorphine prescription or 30 days without meeting with provider have passed.
Changes in multidimensional problem severity from baseline through one year post-study entry At baseline and 3,6,9, 12-month assessments Multidimensional problem severity, a secondary outcome, will be measured using the Addiction Severity Index-Lite (ASI-Lite). The ASI-Lite is a reliable and valid multidimensional assessment that provides composite scores reflecting current problem severity in the medical, employment, alcohol, drug, legal, family/social, and psychiatric areas. Scores may range from 0 to 1 with higher scores indicating greater problem severity.
Changes in treatment satisfaction from baseline to one year post-study entry At baseline and 3,6,9, 12-month assessments Treatment satisfaction will be measured using a subscale from the Client Satisfaction Questionnaire-8 (19). The CSQ-8 measures patient therapeutic engagement in and satisfaction with treatment. Scores may range from 8 to 32 with higher scores indicating greater treatment satisfaction.
Changes in quality of life assessment: Short Form-36 (SF-36) from baseline through one year post-study entry At baseline and 3,6,9, 12-month assessments Quality of life will be measured using the Short Form-36 (SF-36). The SF-36 is a self-report inventory that assesses eight dimensions of physical and mental health-related quality of life. The SF-36 has been shown to have high reliability and validity. For each subscale, scores may range from 0 to 100 with higher scores reflecting greater quality of life.
Changes in opioid overdose rates At baseline and 3,6,9, 12-month assessments The ASI-Lite (see above) captures the number of opioid overdoses that a patient experienced during the given timeframe (i.e., past 90 days). In addition, opioid overdoses will be extracted from the patient's clinical record.
Changes in ED utilization from baseline to one year post-study entry At baseline and 3,6,9, 12-month assessments The ASI-Lite (see above) captures the number of ED visits that the patient experienced during the given timeframe (i.e., past 90 days).
Trial Locations
- Locations (1)
Philadelphia College of Osteopathic Medicine
🇺🇸Philadelphia, Pennsylvania, United States